tbuckley/cabot-search huggingface dataset:
Deficiency of NPR-C triggers high salt-induced thoracic aortic dissection by impairing mitochondrial homeostasis
Authors: Jin-Qiu Wei, Yi Yang, Wen-Hui Zhai, Jia-Jia Zhao, Yi-Hang Yang, Yuan-Yuan Kang, Qi-Fang Huang, Wei Zhang, Wu-Wei Rong, Qian-Wan Deng, Jing Chen, Xiao-Fei Ye, Ping-Jin Gao, Zhe Wang, Xiao-Dong Li, Ji-Guang Wang
Journal: Cardiovascular Research (2025)

Abstract Aims Thoracic aortic dissection (TAD) is a highly fatal disease lacking effective pharmacologic interventions in clinical practice. Emerging evidence indicates that the natriuretic peptide receptor C (NPR-C) plays a crucial role in the regulation of cardiovascular diseases. However, the precise involvement of NPR-C in TAD remains elusive. In this study, the role and molecular mechanisms of NPR-C in the pathogenesis of TAD were investigated. Methods and Results Through integrated analyses of human TAD transcriptome and single-cell sequencing data sets, we identified that NPR-C was downregulated in the aortas of acute TAD patients and in beta-aminopropionitrile (BAPN)-treated mice. Intriguingly, vascular smooth muscle cell (VSMC)-specific NPR-C knockout (NPR-CSMKO) mice, rather than endothelial cell-specific NPR-C knockout mice, developed TAD after treated with angiotensin II (Ang II) plus high salt diet (HSD), but not Ang II alone. Loss of NPR-C function promoted extracellular matrix degeneration, VSMCs apoptosis and inflammation. RNA-sequencing analysis revealed that mitochondrial fatty acid oxidation (FAO) genes were significantly downregulated in the thoracic aortas of NPR-CSMKO mice treated with Ang II plus HSD. Notably, the expression of HADHB, a subunit of mitochondrial trifunctional protein (MTP) responsible for FAO, was obviously decreased in NPR-CSMKO mice treated with Ang II plus HSD. Mechanistically, knockdown of NPR-C activated ERK1/2 pathway, which decreased the expression and activity of peroxisome proliferator-activated receptor γ (PPARγ) and inhibited HADHB expression. Furthermore, NPR-C agonist, C-ANP4-23, mitigated the progression of TAD in BAPN-treated mice. Activation of MTP by spermidine (SPD) effectively prevented TAD formation in NPR-CSMKO mice treated with Ang II plus HSD. Conclusions Our data highlight a critical role of HSD in triggering TAD and a previously unrecognized role of NPR-C that protects against TAD through regulating mitochondrial homeostasis. Therefore, NPR-C activation and SPD supplementation could be new prevention and treatment strategies for TAD.
Novel roles of Nrf3-Trim5 axis in vascular smooth muscle cell dysfunctions and neointimal hyperplasia
Authors: Qishan Chen, Shasha Sun, Zhenning Shi, Leyu Wang, Yumeng Wang, Ancheng Zheng, Xiaolei Xu, Mei Yang, Kun Sun, Qingzhong Xiao, Li Zhang
Journal: Cardiovascular Research (2025)

Abstract Aims Neointimal hyperplasia (NIH) characterized by vascular smooth muscle cell (VSMC) dysfunctions plays a critical role in many vascular diseases including atherosclerosis and restenosis, which leads to serious ischemic complications and has limited therapeutic approaches. Our previous studies confirm a critical role for nuclear factor erythroid 2-related factor 3 (Nrf3) in VSMC differentiation. However, little is known about the functional implications of Nrf3 in NIH. Methods and Results Transcriptome dataset and human atherosclerotic samples were used to determine Nrf3 expression levels. Global (Nrf3-/-) and VSMC-specific (Nrf3ΔSMC) Nrf3 knockout mice were used to assess the role of Nrf3 in VSMC function and injury-induced NIH. Complementary molecular methods were performed to identify Nrf3 downstream targets and elucidate the regulatory role of Nrf3 in target gene regulation. Porcine carotid stenting model was used to validate the therapeutic effects of Nrf3 inhibition in vascular remodeling. Transcriptomic data and immunostaining analysis showed increased levels of Nrf3, and a positive correlation between Nrf3 and NIH in the human atherosclerotic vessels. Various pathophysiological stimuli induced endoplasmic reticulum (ER) stress which enhanced Nrf3 expression via Activating Transcription Factor 4 (ATF4). Nrf3 overexpression promoted both human and mouse VSMC proliferation, migration, and inflammatory response, while opposite effects were observed when Nrf3 was deleted or knockdown. Nrf3-/- and Nrf3ΔSMC mice showed decreased VSMC accumulation and attenuated vascular injury-induced NIH. Mechanistically, tripartite motif-containing 5 (Trim5), a genetic risk locus for coronary artery disease, was identified as a functional downstream target of Nrf3 in VSMCs and in injured arteries. Nrf3 enhanced autophagy in VSMCs and injured arteries by upregulating Trim5 expression, which subsequently promoted dysfunctions of VSMCs, thereby increasing injury-induced NIH. Importantly, restoring either Nrf3 or Trim5 expression in Nrf3-/- mice rescued the arterial phenotypes observed in Nrf3-/- mice. Critically, the porcine carotid artery restenosis induced by ballooning and stenting was significantly reduced by suppressing Nrf3 expression through perivascular administration of the Nrf3 inhibitors. Conclusions We comprehensively demonstrate that Nrf3 is a novel modulator in VSMC dysfunctions and injury-induced NIH. Nrf3 exerts its pathological functions by transcriptional activation of Trim5 gene, which in turn triggers autophagy in VSMCs and injured arteries, promoting arterial remodeling. Inhibiting the Nrf3-Trim5 signal axis ameliorates injury-induced NIH, offering novel therapeutics for treating patients with NIH-related vascular diseases.
Tryptophan-producing bacteria to mitigate osteoporosis and intestinal dysfunction
Authors: Bo Tian, Heng Wang, Yue Zhang, Jinmin Lv, Dongxiao Li, Chenmeng Zhou, Jialu Xu, Yichao Ni, Bingbing Wu, Mingchao Zhang, Huaxing Dai, Fang Xu, Jinyu Bai, Chao Wang, Xiaozhong Zhou
Journal: Bioactive Materials (2025)
FedWeight: mitigating covariate shift of federated learning on electronic health records data through patients re-weighting
Authors: He Zhu, Jun Bai, Na Li, Xiaoxiao Li, Dianbo Liu, David L Buckeridge, Yue Li
Journal: npj Digital Medicine (2025)

Federated learning (FL) enables collaborative analysis of decentralized medical data while preserving patient privacy. However, the covariate shift from demographic and clinical differences can reduce model generalizability. We propose FedWeight, a novel FL framework that mitigates covariate shift by reweighting patient data from the source sites using density estimators, allowing the trained model to better align with the distribution of the target site. To support unsupervised applications, we introduce FedWeight ETM, a federated embedded topic model. We evaluated FedWeight in cross-site FL on the eICU dataset and cross-dataset FL between eICU and MIMIC III. FedWeight consistently outperforms standard FL baselines in predicting ICU mortality, ventilator use, sepsis diagnosis, and length of stay. SHAP-based interpretation and ETM-based topic modeling reveal improved identification of clinically relevant characteristics and disease topics associated with ICU readmission.
Hybrid machine learning for real-time prediction of edema trajectory in large middle cerebral artery stroke
Authors: Ethan Phillips, Odhran O'Donoghue, Yumeng Zhang, Panos Tsimpos, Leigh Ann Mallinger, Stefanos Chatzidakis, Jack Pohlmann, Yili Du, Ivy Kim, Jonathan Song, Benjamin Brush, Stelios Smirnakis, Charlene J Ong, Agni Orfanoudaki
Journal: npj Digital Medicine (2025)

In treating malignant cerebral edema after a large middle cerebral artery stroke, clinicians need quantitative tools for real-time risk assessment. Existing predictive models typically estimate risk at one, early time point, failing to account for dynamic variables. To address this, we developed Hybrid Ensemble Learning Models for Edema Trajectory (HELMET) to predict midline shift severity, an established indicator of malignant edema, over 8-h and 24-h windows. The HELMET models were trained on retrospective data from 623 patients and validated on 63 patients from a different hospital system, achieving mean areas under the receiver operating characteristic curve of 96.6% and 92.5%, respectively. By integrating transformer-based large language models with supervised ensemble learning, HELMET demonstrates the value of combining clinician expertise with multimodal health records in assessing patient risk. Our approach provides a framework for accurate, real-time estimation of dynamic clinical targets using human-curated and algorithm-derived inputs.
The DRAGON benchmark for clinical NLP
Authors: Joeran S Bosma, Koen Dercksen, Luc Builtjes, Romain André, Christian Roest, Stefan J Fransen, Constant R Noordman, Mar Navarro-Padilla, Judith Lefkes, Natália Alves, Max J J de Grauw, Leander van Eekelen, Joey M A Spronck, Megan Schuurmans, Bram de Wilde, Ward Hendrix, Witali Aswolinskiy, Anindo Saha, Jasper J Twilt, Daan Geijs, Jeroen Veltman, Derya Yakar, Maarten de Rooij, Francesco Ciompi, Alessa Hering, Jeroen Geerdink, Henkjan Huisman
Journal: npj Digital Medicine (2025)

Artificial Intelligence can mitigate the global shortage of medical diagnostic personnel but requires large-scale annotated datasets to train clinical algorithms. Natural Language Processing (NLP), including Large Language Models (LLMs), shows great potential for annotating clinical data to facilitate algorithm development but remains underexplored due to a lack of public benchmarks. This study introduces the DRAGON challenge, a benchmark for clinical NLP with 28 tasks and 28,824 annotated medical reports from five Dutch care centers. It facilitates automated, large-scale, cost-effective data annotation. Foundational LLMs were pretrained using four million clinical reports from a sixth Dutch care center. Evaluations showed the superiority of domain-specific pretraining (DRAGON 2025 test score of 0.770) and mixed-domain pretraining (0.756), compared to general-domain pretraining (0.734, p < 0.005). While strong performance was achieved on 18/28 tasks, performance was subpar on 10/28 tasks, uncovering where innovations are needed. Benchmark, code, and foundational LLMs are publicly available.
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
Authors: Matthew G Krebs, Byoung Chul Cho, Sandrine Hiret, Ji-Youn Han, Ki Hyeong Lee, Casilda Llácer Pérez, Filippo De Braud, Eric B Haura, Rachel E Sanborn, James Chih-Hsin Yang, Catherine A Shu, Koichi Goto, Makoto Nishio, Jun Zhao, Zhijie Wang, Pascale Tomasini, Enriqueta Felip, Jonathan W Goldman, Sai-Hong Ignatius Ou, Michael Boyer, Grace Gao, Siyang Qu, Joshua C Curtin, Xuesong Lyu, Robert W Schnepp, Priya Kim, Meena Thayu, Roland E Knoblauch, Patricia Lorenzini, Mahadi Baig, Alexander I Spira, Natasha B Leighl
Journal: Journal of Thoracic Oncology (2025)
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study
Authors: J N Graff, M Burotto, P C Fong, D W Pook, B Zurawski, R M Kopp, J Salinas, K A Bylow, G Kramer, R Ratta, M Kwiatkowski, M Retz, C Kwak, J A Arranz Arija, H Gurney, N Matsubara, L Villanueva, T Todenhöfer, L W Liang, J Todoric, K Imai, A Stenzl
Journal: Annals of Oncology (2025)
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
Authors: C Gratzke, M Özgüroğlu, A Peer, M A N Sendur, M Retz, J C Goh, W Loidl, G Jayram, S-S Byun, C Kwak, M Kwiatkowski, R M Kopp, J C V Limón, J F E Penagos, U De Giorgi, K M da Trindade, C Niu, Y Liu, C H Poehlein, J M Piulats
Journal: Annals of Oncology (2025)
Cannabidiol-loaded hydrogel contact lenses for on-demand pH regulation and enhanced corneal alkali burn repair
Authors: Hongyan Zhang, Ling-Min Lan, Han-Jian Hu, Yu Chen, Tian Hu, Hao Cheng, Xiaolong Hu, Shipeng Tang, Xiao-Ping Liao, Gang-Biao Jiang
Journal: Journal of Controlled Release (2025)
Highly pure mRNA vaccine provides robust immunization against P. aeruginosa by minimizing type I interferon responses
Authors: Ken Kawaguchi, Le Bui Thao Nguyen, Mao Kinoshita, Naoko Abe, Makoto Oba, Hiroshi Abe, Kazuki Sudo, Keita Inoue, Satoshi Uchida, Teiji Sawa
Journal: Journal of Controlled Release (2025)
Microneedle-adapted PAMAM-BSH delivery facilitates spatiotemporal matching for melanoma boron neutron capture therapy
Authors: Qiuyang Liu, Linwen Lv, Hao Li, Haojun Liang, Fan Hu, Wenxi Su, Junhui Zhang, Ranran Chen, Ziteng Chen, Zhijie Wang, Ruyu Yan, Jun Chen, Yanan Chang, Juan Li, Hui Yuan, Gengmei Xing, Kui Chen
Journal: Journal of Controlled Release (2025)
M2 macrophage-targeted metal-polyphenol networks (MPNs) for OPN siRNA delivery and idiopathic pulmonary fibrosis therapy
Authors: Shudan Zheng, Zhenghao Zhou, Jie Ji, Yuxin Liu, Xiaodan Jiao, Xiaoyang Li, Yi Shen, Hao Hong, Xiaodong Han
Journal: Journal of Controlled Release (2025)
Novel Coronaviruses Identified in Livestock: The Urgent Need to Enhance Coronavirus Surveillance to Mitigate Zoonotic Risks
Authors: Kaili Qi, Jie Chen, Xing Ma, Dongyan Li, Guy Baele, Xinxin Li, Ying Qin, Xiang Ji, Mengmeng Zhu, Xin-Xin Li, Dawei Guo, Andres Merits, Michael Veit, Xiaofeng Zhai, Jin Tian, Ningning Wang, Houqi Jiao
Journal: Journal of Infection (2025)
The Impact of Lifestyle Factors on Cardiometabolic Comorbidities and Mortality of Psoriatic Diseases: A Multi-State Model Analysis
Authors: Yi Xiao, Songchun Yang, Yang Zhang, Yixuan Tong, Danrong Jing, Yinli Zhou, Hui Xiao, Yehong Kuang, Minxue Shen, Xiang Chen
Journal: Journal of the American Academy of Dermatology (2025)
Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic-Resistant Organisms (FERARO): a feasibility randomised controlled trial
Authors: Blair Merrick, Désirée Prossomariti, Elizabeth Allen, Karen Bisnauthsing, Michael Kertanegara, Chrysi Sergaki, Adrien D Le Guennec, Marc Delord, Jordana T Bell, Maria R Conte, David L Moyes, Manu Shankar-Hari, Abdel Douiri, Anna L Goodman, Debbie L Shawcross, Simon D Goldenberg
Journal: Journal of Infection (2025)
Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis
Authors: Robert Bissonnette, Linda Stein Gold, Leon Kircik, Eric L Simpson, Lawrence F Eichenfield, John Browning, Adelaide A Hebert, Andrew F Alexis, Weily Soong, Stephen C Piscitelli, Anna M Tallman, David S Rubenstein, Philip M Brown, Jonathan I Silverberg
Journal: Journal of the American Academy of Dermatology (2025)
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study
Authors: Ujjwal M Mahajan, Bettina Oehrle, Elisabetta Goni, Oliver Strobel, Jörg Kaiser, Robert Grützmann, Jens Werner, Helmut Friess, Thomas M Gress, Thomas W Seufferlein, Waldemar Uhl, Uwe Will, John P Neoptolemos, Uwe A Wittel, Marlies Vornhülz, Simon Sirtl, Georg Beyer, Ivonne Regel, Stefan Boeck, Volker Heinemann, Fabian Frost, Antje Steveling, Henry Völzke, Astrid Petersmann, Matthias Nauck, Eckhard Weber, Beate Kamlage, Markus M Lerch, Julia Mayerle, Ali-Alexander Aghdassi, Peter Simon, Frank-Ulrich Weiss, Matthias Sendler, Maximilian Brunner, Daniel Reim, Markus W. Büchler, Thilo Hackert, Tobias Grote, Alexander Kleger, Thomas Ettrich, Angelika Kestler, Wolff Schmiegel, Michael Pohl, Deepak Vangala, Albrecht Hoffmeister, Arndt Vogel, Heiner Wedemeyer, Chris Braumann, Patrick Michl, Jonas Rosendahl, Jakob R. Izbicki, Jochen Hampe, Stefan Sulk, Sebastian Zeissig, Andreas Stallmach, Stephan Kruger, Malte Schirren, Jan D'Haese, Martin Fuchs, Wolfgang Schepp, Marcus Bahra, Johann Pratschke, Viliam Masaryk, Markus Dollhopf, Maximilian Reichert, Ingo Klein, Jochen Wedemeyer
Journal: The Lancet. Gastroenterology & hepatology (2025)
Radiate equity: the inclusion of radiation oncology and other specialties in lymphoma collaborative groups
Authors: Omran Saifi, Chelsea C Pinnix, Chris R Kelsey, Leslie K Ballas, Sarah A Milgrom, Ranjana Advani, Margaret T Kasner, Stella Flampouri, Stephanie A Terezakis, Mark Sellmyer, John P Plastaras, Bradford S Hoppe
Journal: The Lancet Haematology (2025)
The imaging crisis in axial spondyloarthritis
Authors: Torsten Diekhoff, Denis Poddubnyy
Journal: The Lancet Rheumatology (2025)

Imaging holds a pivotal yet contentious role in the early diagnosis of axial spondyloarthritis. Although MRI has enhanced our ability to detect early inflammatory changes, particularly bone marrow oedema in the sacroiliac joints, the poor specificity of this finding introduces a substantial risk of overdiagnosis. The well intentioned push by rheumatologists towards earlier intervention could inadvertently lead to the misclassification of mechanical or degenerative conditions (eg, osteitis condensans ilii) as inflammatory disease, especially in the absence of structural lesions. Diagnostic uncertainty is further fuelled by anatomical variability, sex differences, and suboptimal imaging protocols. Current strategies-such as quantifying bone marrow oedema and analysing its distribution patterns, and integrating clinical and laboratory data-offer partial guidance for avoiding overdiagnosis but fall short of resolving the core diagnostic dilemma. Emerging imaging technologies, including high-resolution sequences, quantitative MRI, radiomics, and artificial intelligence, could improve diagnostic precision, but these tools remain exploratory. This Viewpoint underscores the need for a shift in imaging approaches, recognising that although timely diagnosis and treatment is essential to prevent long-term structural damage, robust and reliable imaging criteria are also needed. Without such advances, the imaging field risks repeating past missteps seen in other rheumatological conditions.
PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma
Authors: Michel Ducreux, Romain Desgrippes, Yves Rinaldi, Frédéric Di Fiore, Rosine Guimbaud, Ludovic Evesque, Jean-Baptiste Bachet, Pierre Vanelslander, Thierry Lecomte, Olivier Capitain, Aurélie Parzy, Marion Bolliet, Pierre-Luc Etienne, Julien Forestier, Farid El Hajbi, Anne-Laure Bignon, Valérie Lebrun-Ly, Nicolas De Sousa Carvalho, Matthieu Texier, Olivier Bouche
Journal: Journal of Clinical Oncology (2025)

PURPOSE More than 30% of patients with pancreatic cancer are unresectable because of the local extension with a median overall survival (OS) of &lt;1 year. Combination of fluorouracil (FU), oxaliplatin, and irinotecan (FOLFIRINOX) is superior to gemcitabine in the treatment of metastatic pancreatic cancer, but standard of care remains gemcitabine in locally advanced pancreatic cancer (LAPC). METHODS Patients with histologically proven LAPC not suitable for surgery, Eastern Cooperative Oncology Group WHO performance status (PS) ≤1 were eligible. Random assignment was stratified by center, tumor localization (pancreas head yes/no), WHO PS (0 v 1), and age (≤60 years v &gt;60 years). Patients received FOLFIRINOX or gemcitabine for 6 months. The primary end point was progression-free survival (PFS). Main secondary end points were OS, time to treatment failure, quality of life, and safety. One hundred seventy patients (142 events) were needed to detect an increase of 3 months in PFS with 80% power (log-rank test, 5% two-sided α). RESULTS One hundred seventy one patients age 35-84 years were included and followed for a maximum of 5 years. With a median follow-up of 59.6 months (95% CI, 42.3 to not reached), 168 events were observed and the median PFS was 9.7 months (95% CI, 7.0 to 11.7) with FOLFIRINOX versus 7.7 months (95% CI, 6.2 to 9.2) with gemcitabine, hazard ratio (HR), 0.7 (95% CI, 0.5 to 1.0), P = .04. The median OS was 15.7 months (95% CI, 11.9 to 20.4) in the FOLFIRINOX group versus 15.4 months (95% CI, 11.7 to 18.6) in the gemcitabine group, HR, 1.02 (95% CI, 0.73 to 1.43), P = .95. CONCLUSION Results confirm that FOLFIRINOX improves PFS significantly compared with gemcitabine and is well tolerated in LAPC. No significant difference in OS was observed between both groups.
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer
Authors: Hisato Kawakami, Shigenori Kadowaki, Akitaka Makiyama, Masahiro Tsuda, Kenro Hirata, Naotoshi Sugimoto, Nozomu Machida, Hiroki Hara, Hidekazu Hirano, Taito Esaki, Yoshito Komatsu, Shuichi Hironaka, Yukari Kobayashi, Kazuhiro Kakimi, Yasutaka Chiba, Narikazu Boku, Ichinosuke Hyodo, Kei Muro
Journal: Journal of Clinical Oncology (2025)

PURPOSE Microsatellite instability–high (MSI-H) advanced gastric or esophagogastric junction cancer (AGC), accounting for 5%-6% of all AGC cases, has shown an enhanced responsiveness to immunotherapy. We performed a single-arm phase II study to evaluate the combination of nivolumab (NIVO) and low-dose (LD) ipilimumab (IPI) for first-line treatment of MSI-H AGC. PATIENTS AND METHODS Patients with MSI-H AGC received NIVO (240 mg once every 2 weeks) and IPI (1 mg/kg once every 6 weeks). The primary end point was overall response rate (ORR) assessed by blinded independent central review. Secondary end points included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), safety, and biomarker analysis. MSI-H status was confirmed with an MSI-IVD Kit (Falco). RESULTS Twenty-nine patients were enrolled. The ORR was 62.1% (95% CI, 42.3 to 79.3), with a complete response rate of 10.3%. The DCR was 79.3% (95% CI, 60.3 to 92.0). Treatment-related adverse events (TRAEs) of any grade occurred in 93.1% of patients, with those of grade ≥3 manifesting in 37.9% of patients. At the data cutoff (median follow-up of 9.0 months), treatment had been discontinued in 21 patients, with such discontinuation being due to TRAEs in 12 (41.4%) patients. However, after exclusion of one patient with progressive disease, the remaining 11 patients showed long-term antitumor efficacy after treatment discontinuation (range of response duration, 0.9+ to 15.6+ months). The median PFS was 13.8 months (95% CI, 13.7 months to not reached [NR]) and the median OS was NR (95% CI, 13.7 months to NR), with a 12-month OS rate of 79.5%. CONCLUSION NIVO plus LD-IPI showed robust and durable antitumor efficacy as a first-line treatment for MSI-H AGC. Although TRAEs often led to treatment discontinuation, treatment efficacy was subsequently sustained in most patients.
Re: Local Anaesthetic Transperineal Biopsy Versus Transrectal Prostate Biopsy in Prostate Cancer Detection (TRANSLATE): A Multicentre, Randomised, Controlled Trial
Authors: David Hennes, Abdullah Al-Khanaty, David C Chen, Eoin Dineen, Christa Babst, Nathan Lawrentschuk, Marlon L Perera, Declan G Murphy
Journal: European Urology (2025)